Opinion

Video

CHEST 2024: Updates in IPF and PAH Care

Key Takeaways

  • Development of therapies that halt or reverse IPF and PAH progression is a significant unmet need.
  • Improved diagnostic tools are essential for earlier detection and intervention in IPF and PAH.
SHOW MORE

Coming into CHEST 2024, Steven Nathan, MD, discusses how the largest unmet needs in the treatment and management of IPF and PAH include improving early diagnosis, addressing symptom management (particularly chronic cough), and developing more effective, accessible therapies to enhance long-term patient outcomes.

1. Coming into CHEST 2024, what would you consider to be the largest unmet needs in the treatment and management of IPF and PAH?

Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo